Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme.

MLA

Krauss, J., et al. “Impact of Antibody Framework Residue VH-71 on the Stability of a Humanised Anti-MUC1 ScFv and Derived Immunoenzyme.” British Journal of Cancer, vol. 90, no. 9, May 2004, pp. 1863–70. EBSCOhost, https://doi.org/10.1038/sj.bjc.6601759.

APA

Krauss, J., Arndt, M., Zhu, Z., Newton, D., Vu, B., Choudhry, V., Darbha, R., X Ji, Courtenay-Luck, N., Deonarain, M. P., Richards, J., Rybak, S. M., Arndt, M. A. E., Newton, D. L., Vu, B. K., Ji, X., & Courtenay-Luck, N. S. (2004). Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme. British Journal of Cancer, 90(9), 1863–1870. https://doi.org/10.1038/sj.bjc.6601759

Chicago

Krauss, J., Mae Arndt, Z. Zhu, Dl. Newton, Bk. Vu, V. Choudhry, R. Darbha, et al. 2004. “Impact of Antibody Framework Residue VH-71 on the Stability of a Humanised Anti-MUC1 ScFv and Derived Immunoenzyme.” British Journal of Cancer 90 (9): 1863–70. doi:10.1038/sj.bjc.6601759.